Domenica M. Rubino, ENDO 2021: Findings from the STEP 4 Study
It was a pleasure to talk to Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA, US) around the effect of once-weekly semaglutide on weight loss maintenance in overweight or obese adults.
‘Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4).‘ (PRESENTATION NUMBER: OR02-3) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
- What are the current unmet needs in the management of adults with obesity? (0:13)
- What was already known about the weight loss benefits of semaglutide in people with obesity? (2:13)
- What were the aims and design of the STEP 4 study, and what were the findings? (3:16)
- What were the safety findings of this study? (4:55)
- What have we learned about the need for long-term treatment with semaglutide? (6:54)
Disclosures: Clinical investigator for NovoNordisk, Boehringer Ingelheim and Astra Zeneca; speaker, consultant and shareholder for NovoNordisk; received speaker honoraria from WebMD/Medscape; grant recipient of Obesinov SARL.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!